The emergence of biomarking testing has provided new insights into the molecular and genetic underpinnings of many types of cancer as well as differences in an individual patient’s cancer at the molecular level. These differences, or alterations (also known as…
On December 11 and 18, 2020 the U.S. Food and Drug Administration (FDA) issued two COVID-19 vaccines, Pfzier BioNTech and Moderna, with emergency use authorization (EUA). LRF Scientific Advisory Board Member, John Leonard, MD (NewYork-Presbyterian Hospital, Weill Cornell Medicine) answered…
In May 2020, lymphoma-expert, Raghuveer Ranganthan, MD (Univerity of Southern California) hosted the Lymphoma Research Foundation’s Update on CAR T-Cell Therapy in Diffuse Large B-cell Lymphoma Webinar. Due to the interest surrounding CAR T-cell therapy to treat various types of…
During the Lymphoma Research Foundation’s Denver Ask the Doctor About Lymphoma Program, lymphoma-expert and program host, John M. Burke, MD (Rocky Mountain Cancer Center), provided the following answer to this question: How can patients access innovative drug treatments when insurance…
